OTCA22 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Point-of-care Tests (POCT): D-Dimer and Troponin’ are now available for access. Troponin and D-dimer point of care tests can be used to aid the diagnosis of patients with symptoms suggestive of suspected acute coronary syndrome and venous thromboembolism respectively. This report aimed […]
November 2019 Implementation Report – Now Available
EUnetHTA is pleased to announce the new Implementation Report with Appendices are now available for access. The report covers the updated use and uptake on all Joint Action 3 assessments. The report and all related documentation is available at this link, or via the National Uptake and Case Studies visuals here.
PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.
The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access the final project plan at the following link: PTJA06 Final Project Plan
OTCA17 – Final Assessment Report and related documents now available
The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)’ are now available for access. The present assessment addressed the research question whether the lithium triborate (LBO) laser for photoselective vaporisation of the […]
PTJA08 – “Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity” project plan now available.
The Final Project Plan of the assessment on siponimod is now available. The final assessment report will be published on 13th February, 2020. Please access the Final Project Plan at the following link: PTJA08 Final Project Plan
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the replies of the author, are now available for access. The health technology assessed is a […]
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’, together with the fact check comments from manufacturers and comments from external experts including the replies of the author, are now available for access. The health technology assessed is a […]
OTCA18 Final Assessment Report is now available.
The final assessment report and related documents concerning OTCA18, ‘regional hyperthermia for high-risk soft tissue sarcoma treatment’, are now available. The assessed technology is regional hyperthermia added to conventional therapies to treat high-risk soft tissue sarcoma. The objective of this rapid relative effectiveness assessment was to collaboratively address the research question: Is the regional application […]
Open Call for Patient Input for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum (NMOSD) disorders.
Patient group input requested for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum disorders. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or […]
PTJA13 – Publication of Project Plan.
PTJA13 – Satralizumab is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive – the project plan is now available. Due to unexpected changes to the timelines of […]